Healthcare & Pharma
Research Without Compromise.
Share Insights, Not Records
Designed for HIPAA-Compliant Workflows
Pharma, payers, and providers unlock clinical and commercial insights by collaborating in Placino, without moving, copying, or exposing a single patient record.
$72M
Modeled ROI Potential
93%
Modeled Enrollment Speedup
12x
Modeled Cohort Scale
Modeled scenarios based on platform capabilities, not customer results.
Explore Use CasesThe Healthcare Data Paradox
The most regulated industry has the most to gain from collaboration, and the most to lose from doing it wrong.
BEFORE PLACINO
HIPAA Fortress
Healthcare data sharing is legally hazardous. A single breach can carry severe penalties. Most organizations choose to share nothing rather than risk everything.
Impact
Severe penalty exposure per violation
BEFORE PLACINO
Trial Recruitment Crisis
Clinical trials routinely miss enrollment deadlines. The patients exist: they are just invisible across fragmented health systems.
Impact
Trials routinely miss enrollment deadlines
BEFORE PLACINO
Evidence Gaps
Payers demand real-world evidence for reimbursement. But the data is locked in separate EHR systems, claims databases, and pharmacy records that cannot be combined.
Impact
Heavy spend on underpowered studies
5 Ways to Win
Modeled scenarios: what the platform makes possible
Clinical Trial Matching
A top-10 pharma company has spent 14 months recruiting patients for a Phase III oncology trial across five hospital networks, and is still at 40% enrollment. Each hospital manually screens charts against eligibility criteria, a process that takes coordinators 45 minutes per patient. Meanwhile, the trial burns $1.2M per month in fixed costs. The eligible patients exist across these networks: they are just invisible because HIPAA prevents hospitals from sharing patient-level data with pharma.
Real-World Evidence Generation
A pharma company must generate post-market drug effectiveness data for reimbursement negotiations with a national payer, but patient-level data is locked in fragmented health systems. Individual studies from single payers produce statistically underpowered cohorts (n=2,400), insufficient to satisfy FDA and EMA guidance for biosimilar equivalence claims. The pharma company faces either a costly $8M RCT or losing reimbursement coverage across a $500M market.
Population Health Analytics
A regional health system serves 1.2M patients, the insurer covers 800K, but only 280K overlap in shared records. Each organization has incomplete visibility: the health system misses out-of-network claims, the insurer misses inpatient episodes. As a result, neither can identify the full 340K-patient cohort with diabetes + hypertension who are at high risk for preventable strokes and heart attacks. Missed prevention opportunities cost the region $200M annually in emergency care.
Pharma Commercial Analytics
A pharma brand has spent $80M annually on DTC advertising campaigns but lacks deterministic proof of script lift. Survey-based measurement suggests only 11% of scripts come from DTC exposure, forcing the brand to cut budget. Yet the pharmacy chain, which owns patient-level prescription records and ad exposure logs, cannot share raw data due to privacy regulation. The brand faces budget cuts in a growth-stage product without real evidence of ROI.
Medical Device Outcome Tracking
A device manufacturer relies on hospital voluntary adverse event reporting for FDA post-market surveillance, but captures only 35% of actual implant complications because hospitals manually code events and submit sparse forms. A safety signal (unusual infection rate post-device revision surgery) exists in hospital EHR data but remains invisible to the manufacturer. Meanwhile, the hospital cannot share raw surgical records due to patient privacy concerns, and the manufacturer cannot legally contact patients directly. The delay in signal detection could result in regulatory action or patient harm.
From Data Silos to Shared Evidence
Without Placino
Clinical trials miss enrollment by 6+ months
Real-world evidence limited to single-site data
Population health gaps invisible across systems
DTC campaign ROI measured by surveys only
Device outcomes tracked at 35% capture rate
With Placino
Trial enrollment completed in 5 weeks vs 18 months
12x larger evidence cohorts accepted by regulators
340K at-risk patients identified for preventive care
DTC script lift measured deterministically at 3.1x ROAS
Device outcome capture increased to 80%
ROI by Use Case
Illustrative ranges from modeled scenarios. Click to explore
Trial Matching
Investment
$800K
First-Year Return
$4.5M
ROI Multiple
5.6x
Full Evidence
Investment
$2M
First-Year Return
$12M
ROI Multiple
6.0x
Multi-Use Case
Investment
$3.5M
First-Year Return
$25M
ROI Multiple
7.1x
Ready to Accelerate Research Safely?
In modeled scenarios, health systems, pharma companies, and payers unlock $72M in combined ROI from trial matching, real-world evidence, and population health analytics.